„Inclisiran“ – Versionsunterschied
| [ungesichtete Version] | [ungesichtete Version] |
Inhalt gelöscht Inhalt hinzugefügt
K comment ATC | |||
| Zeile 50: | Zeile 50: | ||
'''Inclisiran''' (development codes '''ALN-PCSsc''', '''ALN-60212''') is an experimental drug for the treatment of [[familial hypercholesterolaemia]]. It is a [[small interfering RNA]] that inhibits [[translation (biology)|translation]] of the protein [[PCSK9]].<ref>{{cite journal|title=A Highly Durable RNAi Therapeutic Inhibitor of PCSK9|journal=New England Journal of Medicine|volume=376|issue=1|pages=41–51|doi=10.1056/NEJMoa1609243|pmid=27959715|year=2017|last1=Fitzgerald|first1=Kevin|last2=White|first2=Suellen|last3=Borodovsky|first3=Anna|last4=Bettencourt|first4=Brian R|last5=Strahs|first5=Andrew|last6=Clausen|first6=Valerie|last7=Wijngaard|first7=Peter|last8=Horton|first8=Jay D|last9=Taubel|first9=Jorg|last10=Brooks|first10=Ashley|last11=Fernando|first11=Chamikara|last12=Kauffman|first12=Robert S|last13=Kallend|first13=David|last14=Vaishnaw|first14=Akshay|last15=Simon|first15=Amy|pmc=5778873}}</ref><ref name="Spreitzer">{{cite journal | last1 = Spreitzer | first1 = H | title = Neue Wirkstoffe: Inclisiran | journal = Österreichische Apotheker-Zeitung | date = 11 September 2017 | issue = 19/2017 | language = German}}</ref><ref>{{cite journal|title=Proposed INN: List 114|journal=WHO Drug Information|volume=29|issue=4|year=2015|pages=531f|publisher=[[World Health Organization|WHO]]|url=http://www.who.int/medicines/publications/druginformation/issues/PL_114.pdf?ua=1}}</ref> | '''Inclisiran''' (development codes '''ALN-PCSsc''', '''ALN-60212''') is an experimental drug for the treatment of [[familial hypercholesterolaemia]]. It is a [[small interfering RNA]] that inhibits [[translation (biology)|translation]] of the protein [[PCSK9]].<ref>{{cite journal|title=A Highly Durable RNAi Therapeutic Inhibitor of PCSK9|journal=New England Journal of Medicine|volume=376|issue=1|pages=41–51|doi=10.1056/NEJMoa1609243|pmid=27959715|year=2017|last1=Fitzgerald|first1=Kevin|last2=White|first2=Suellen|last3=Borodovsky|first3=Anna|last4=Bettencourt|first4=Brian R|last5=Strahs|first5=Andrew|last6=Clausen|first6=Valerie|last7=Wijngaard|first7=Peter|last8=Horton|first8=Jay D|last9=Taubel|first9=Jorg|last10=Brooks|first10=Ashley|last11=Fernando|first11=Chamikara|last12=Kauffman|first12=Robert S|last13=Kallend|first13=David|last14=Vaishnaw|first14=Akshay|last15=Simon|first15=Amy|pmc=5778873}}</ref><ref name="Spreitzer">{{cite journal | last1 = Spreitzer | first1 = H | title = Neue Wirkstoffe: Inclisiran | journal = Österreichische Apotheker-Zeitung | date = 11 September 2017 | issue = 19/2017 | language = German}}</ref><ref>{{cite journal|title=Proposed INN: List 114|journal=WHO Drug Information|volume=29|issue=4|year=2015|pages=531f|publisher=[[World Health Organization|WHO]]|url=http://www.who.int/medicines/publications/druginformation/issues/PL_114.pdf?ua=1}}</ref> | ||
It is being developed by [[The Medicines Company]] which licensed the rights to inclisiran from [[Alnylam Pharmaceuticals]].<ref>{{cite web |title=Medicines Company's PCSK9 drug hits phase 3 efficacy goals |url=https://www.fiercebiotech.com/biotech/medicines-company-s-pcsk9-drug-hits-phase-3-efficacy-goals |website=FierceBiotech |accessdate=29 August 2019 |language=en}}</ref> | It is being developed by [[The Medicines Company]] which licensed the rights to inclisiran from [[Alnylam Pharmaceuticals]].<ref>{{cite web |title=Medicines Company's PCSK9 drug hits phase 3 efficacy goals |url=https://www.fiercebiotech.com/biotech/medicines-company-s-pcsk9-drug-hits-phase-3-efficacy-goals |website=FierceBiotech |accessdate=29 August 2019 |language=en}}</ref> According to the [[Department of Health and Social Care]], this cure would annually prevent 55,000 heart attacks and strokes for every 300,000 patients.<ref>{{Cite web|url=https://www.bbc.com/news/health-51091083|title=NHS to pioneer cholesterol-busting jab|last=|first=|date=13 January 2020|website=BBC News|url-status=live|archive-url=|archive-date=|access-date=}}</ref> | ||
In 2019 The Medicines Company announced positive results from pivotal phase 3 study (all primary and secondary endpoints were met with efficacy consistent with Phase 1 and 2 studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.<ref>{{cite web |title=The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran |url=https://www.themedicinescompany.com/investor/pr/3992694/ |website=www.themedicinescompany.com |accessdate=29 August 2019 |language=en}}</ref> The Medicines Company is being acquired by [[Novartis]].{{fact|date=November 2019}} | In 2019 The Medicines Company announced positive results from pivotal phase 3 study (all primary and secondary endpoints were met with efficacy consistent with Phase 1 and 2 studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.<ref>{{cite web |title=The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran |url=https://www.themedicinescompany.com/investor/pr/3992694/ |website=www.themedicinescompany.com |accessdate=29 August 2019 |language=en}}</ref> The Medicines Company is being acquired by [[Novartis]].{{fact|date=November 2019}} | ||
Version vom 14. Januar 2020, 11:14 Uhr
Inclisiran (development codes ALN-PCSsc, ALN-60212) is an experimental drug for the treatment of familial hypercholesterolaemia. It is a small interfering RNA that inhibits translation of the protein PCSK9.[1][2][3] It is being developed by The Medicines Company which licensed the rights to inclisiran from Alnylam Pharmaceuticals.[4] According to the Department of Health and Social Care, this cure would annually prevent 55,000 heart attacks and strokes for every 300,000 patients.[5]
In 2019 The Medicines Company announced positive results from pivotal phase 3 study (all primary and secondary endpoints were met with efficacy consistent with Phase 1 and 2 studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.[6] The Medicines Company is being acquired by Novartis.Vorlage:Fact
References
Vorlage:Cardiovascular-drug-stub
- ↑ Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D Horton, Jorg Taubel, Ashley Brooks, Chamikara Fernando, Robert S Kauffman, David Kallend, Akshay Vaishnaw, Amy Simon: A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. In: New England Journal of Medicine. 376. Jahrgang, Nr. 1, 2017, S. 41–51, doi:10.1056/NEJMoa1609243, PMID 27959715, PMC 5778873 (freier Volltext).
- ↑ H Spreitzer: Neue Wirkstoffe: Inclisiran. In: Österreichische Apotheker-Zeitung. Nr. 19/2017, 11. September 2017.
- ↑ Proposed INN: List 114. In: WHO Drug Information. 29. Jahrgang, Nr. 4. WHO, 2015, S. 531 f. (who.int [PDF]).
- ↑ Medicines Company's PCSK9 drug hits phase 3 efficacy goals. In: FierceBiotech. Abgerufen am 29. August 2019 (englisch).
- ↑ NHS to pioneer cholesterol-busting jab. In: BBC News. 13. Januar 2020.
- ↑ The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran. In: www.themedicinescompany.com. Abgerufen am 29. August 2019 (englisch).
